Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Biogen Inc.

(BGEN)

Hancock Institutional analyst Robert Friedman initiated coverage with a "buy" and a one-year target of $50.

Beta interferon holds the key to the Cambridge, Mass., company's success as a fully integrated

Read the full 352 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE